ELMD Quote, Financials, Valuation and Earnings

Cutera has a net margin of 10.05% compared to Electromed's net margin of -120.06%. Electromed's return on equity of 15.62% beat Cutera's return on equity of --.

Electromed has a consensus price target of --, signalling upside risk potential of 15.18%. On the other hand Cutera has an analysts' consensus of -- which suggests that it could grow by 511.06%. Given that Cutera has higher upside potential than Electromed, analysts believe Cutera is more attractive than Electromed.

Electromed has a beta of 0.285, which suggesting that the stock is 71.506% less volatile than S&P 500. In comparison Cutera has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.313%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cutera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Cutera pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $14.7M, which are smaller than Cutera quarterly revenues of $32.5M. Electromed's net income of $1.5M is higher than Cutera's net income of -$39M. Notably, Electromed's price-to-earnings ratio is 39.79x while Cutera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 4.48x versus 0.04x for Cutera. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of 10.05% compared to Electromed's net margin of -16.69%. Electromed's return on equity of 15.62% beat IRIDEX's return on equity of -157.91%.

Electromed has a consensus price target of --, signalling upside risk potential of 15.18%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 26.58%. Given that IRIDEX has higher upside potential than Electromed, analysts believe IRIDEX is more attractive than Electromed.

Electromed has a beta of 0.285, which suggesting that the stock is 71.506% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.837%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $14.7M, which are larger than IRIDEX quarterly revenues of $11.6M. Electromed's net income of $1.5M is higher than IRIDEX's net income of -$1.9M. Notably, Electromed's price-to-earnings ratio is 39.79x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 4.48x versus 0.53x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 10.05% compared to Electromed's net margin of -10.5%. Electromed's return on equity of 15.62% beat Myomo's return on equity of -84.04%.

Electromed has a consensus price target of --, signalling upside risk potential of 15.18%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 27.14%. Given that Myomo has higher upside potential than Electromed, analysts believe Myomo is more attractive than Electromed.

Electromed has a beta of 0.285, which suggesting that the stock is 71.506% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $14.7M, which are larger than Myomo quarterly revenues of $9.2M. Electromed's net income of $1.5M is higher than Myomo's net income of -$966.4K. Notably, Electromed's price-to-earnings ratio is 39.79x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 4.48x versus 8.81x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 10.05% compared to Electromed's net margin of -67.31%. Electromed's return on equity of 15.62% beat Stereotaxis's return on equity of -108.68%.

Electromed has a consensus price target of --, signalling upside risk potential of 15.18%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 91.49%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

Electromed has a beta of 0.285, which suggesting that the stock is 71.506% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $14.7M, which are larger than Stereotaxis quarterly revenues of $9.2M. Electromed's net income of $1.5M is higher than Stereotaxis's net income of -$6.2M. Notably, Electromed's price-to-earnings ratio is 39.79x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 4.48x versus 7.87x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.